4,155 Shares in Alnylam Pharmaceuticals, Inc. $ALNY Bought by United Capital Financial Advisors LLC

United Capital Financial Advisors LLC bought a new stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 4,155 shares of the biopharmaceutical company’s stock, valued at approximately $1,251,000.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Daiwa Securities Group Inc. increased its position in shares of Alnylam Pharmaceuticals by 0.3% in the second quarter. Daiwa Securities Group Inc. now owns 12,941 shares of the biopharmaceutical company’s stock valued at $4,220,000 after acquiring an additional 35 shares during the last quarter. Golden State Wealth Management LLC boosted its position in Alnylam Pharmaceuticals by 100.0% during the fourth quarter. Golden State Wealth Management LLC now owns 72 shares of the biopharmaceutical company’s stock valued at $29,000 after purchasing an additional 36 shares during the last quarter. Coldstream Capital Management Inc. boosted its position in Alnylam Pharmaceuticals by 2.4% during the third quarter. Coldstream Capital Management Inc. now owns 1,640 shares of the biopharmaceutical company’s stock valued at $748,000 after purchasing an additional 38 shares during the last quarter. Atlantic Union Bankshares Corp grew its stake in Alnylam Pharmaceuticals by 20.9% in the fourth quarter. Atlantic Union Bankshares Corp now owns 231 shares of the biopharmaceutical company’s stock valued at $92,000 after purchasing an additional 40 shares in the last quarter. Finally, Laird Norton Wetherby Wealth Management LLC grew its stake in Alnylam Pharmaceuticals by 3.3% in the third quarter. Laird Norton Wetherby Wealth Management LLC now owns 1,266 shares of the biopharmaceutical company’s stock valued at $577,000 after purchasing an additional 40 shares in the last quarter. 92.97% of the stock is owned by institutional investors.

Insider Buying and Selling

In other Alnylam Pharmaceuticals news, Director David E. I. Pyott sold 3,830 shares of the business’s stock in a transaction that occurred on Monday, June 1st. The shares were sold at an average price of $299.18, for a total transaction of $1,145,859.40. Following the sale, the director directly owned 1,582 shares of the company’s stock, valued at $473,302.76. The trade was a 70.77% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.86% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on ALNY shares. Morgan Stanley dropped their price objective on Alnylam Pharmaceuticals from $400.00 to $300.00 and set an “equal weight” rating for the company in a report on Friday, July 31st. Barclays decreased their price target on Alnylam Pharmaceuticals from $527.00 to $450.00 and set an “overweight” rating on the stock in a research report on Monday, August 3rd. Chardan Capital reaffirmed a “buy” rating and issued a $425.00 price target on shares of Alnylam Pharmaceuticals in a research note on Friday, July 31st. Raymond James Financial raised shares of Alnylam Pharmaceuticals from an “outperform” rating to a “strong-buy” rating and set a $420.00 price objective for the company in a research report on Monday, August 3rd. Finally, Truist Financial reduced their price objective on shares of Alnylam Pharmaceuticals from $410.00 to $315.00 and set a “buy” rating on the stock in a research note on Tuesday, August 4th. Three equities research analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and five have assigned a Hold rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $386.14.

Alnylam Pharmaceuticals Price Performance

Alnylam Pharmaceuticals stock opened at $237.10 on Friday. The company has a debt-to-equity ratio of 0.75, a quick ratio of 2.99 and a current ratio of 3.05. Alnylam Pharmaceuticals, Inc. has a 52 week low of $197.81 and a 52 week high of $495.55. The stock has a market capitalization of $31.73 billion, a P/E ratio of 44.07 and a beta of 0.30. The stock has a fifty day moving average of $262.62 and a 200-day moving average of $293.73.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported $1.84 earnings per share for the quarter, topping the consensus estimate of $1.63 by $0.21. Alnylam Pharmaceuticals had a return on equity of 84.93% and a net margin of 15.26%.The business had revenue of $1.29 billion during the quarter, compared to the consensus estimate of $1.32 billion. During the same period in the prior year, the company earned ($0.51) EPS. Alnylam Pharmaceuticals’s revenue for the quarter was up 66.9% on a year-over-year basis. On average, sell-side analysts expect that Alnylam Pharmaceuticals, Inc. will post 6.59 earnings per share for the current fiscal year.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.